KCTD17

Across TCGA pan-cancer cohorts, KCTD17 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated KCTD17 data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher KCTD17 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated KCTD17 expression acts as an unfavorable survival marker.

LSCC, HNSC, and PDAC are the cancer types where KCTD17 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Quartile	All	0.742	1.000	<.001	36	view →
HNSC	DFS	Median	III,IV	0.362	0.922	.006	22	view →
PDAC	DFS	Median	II,III,IV	0.418	0.778	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

KCTD17–LSCC (OS)

Open the LSCC breakdown →